(HealthDay News) – For adults with type 2 diabetes and coronary artery disease, race/ethnicity has no significant impact on the long-term risk of death, according to a study published in the Nov. 1 issue of The American Journal of Cardiology.
As part of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial, Nirat Beohar, MD, from Columbia University in Miami Beach, and colleagues examined the impact of race/ethnicity on cardiovascular risk factor control and on clinical outcomes in a setting with comparable access to medical care. A total of 1,750 adults with type 2 diabetes and coronary artery disease from the United States and Canada were enrolled in the BARI 2D trial, and included 1,189 non-Hispanic whites, 349 non-Hispanic blacks, and 212 Hispanics. Participants were randomized to receive cardiac and glycemic treatment strategies.
During an average follow-up of 5.3 years, the researchers observed no significant variation by race/ethnicity in the long-term risk of death and death/myocardial infarction/stroke (five-year death: 11% whites; 13.7% blacks; 8.7% Hispanics; P=0.19). For the 1,168 patients with suboptimal risk factor control at baseline, higher five-year survival was associated with the ability to attain better risk factor control (71%, 86%, and 95%, respectively, for patients with one, two, or three factors in control); this pattern was seen for all race/ethnicities.
“In conclusion, significant race/ethnic differences in cardiac risk profiles that persisted during follow-up did not translate into significant differences in five-year death or death/myocardial infarction/stroke,” the authors write.
The BARI 2D Trial received funding, medications, and supplies from pharmaceutical companies.